ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,737.99
0.52%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Nektar Therapeutics (NKTR)

  7. Nektar Therapeutics (NKTR) Noticias

NKTR Nektar Therapeutics

1.33
0.01 (0.76%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Nektar Therapeutics NKTR NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.01 0.76% 1.33 23:00:06
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.33 1.31 1.38 1.33 1.32
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
22/3/202413:00PRNUSNektar Management to Present at the H.C. Wainwright 2nd..
05/3/202416:11EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
05/3/202408:00PRNUSNektar Therapeutics Announces Initiation of Phase 2b..
04/3/202415:20EDGAR2Form 8-K - Current report
04/3/202415:15PRNUSNektar Therapeutics Reports Fourth Quarter and Year-End 2023..
04/3/202407:40EDGAR2Form 8-K - Current report
04/3/202407:30PRNUSNektar Therapeutics Announces $30 Million Private Placement..
27/2/202417:00PRNUSNektar Management to Present at the TD Cowen 44th Annual..
26/2/202417:00PRNUSNektar to Announce Financial Results for the Fourth Quarter..
22/2/202419:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202419:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202419:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202414:55EDGAR2Form 144 - Report of proposed sale of securities
20/2/202414:51EDGAR2Form 144 - Report of proposed sale of securities
20/2/202414:50EDGAR2Form 144 - Report of proposed sale of securities
16/2/202416:16EDGAR2Form 8-K - Current report
14/2/202416:03EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202407:50EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/1/202415:25EDGAR2Form 8-K - Current report
03/1/202417:00PRNUSNektar Management To Present at the 42nd Annual J.P. Morgan..
15/12/202317:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202317:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202317:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202311:18EDGAR2Form 144 - Report of proposed sale of securities
11/12/202317:00PRNUSNektar and Collaborators Present Preclinical Data on..
27/11/202315:55EDGAR2Form 8-K - Current report
20/11/202320:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202320:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202319:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202315:36EDGAR2Form 144 - Report of proposed sale of securities
17/11/202315:15EDGAR2Form 144 - Report of proposed sale of securities
17/11/202315:10EDGAR2Form 144 - Report of proposed sale of securities
07/11/202315:21EDGAR2Form 8-K - Current report
07/11/202315:15PRNUSNektar Therapeutics Reports Third Quarter 2023 Financial..
31/10/202317:00PRNUSNektar to Announce Financial Results for the Third Quarter..
13/10/202307:30PRNUSNektar Presents New Responder Data for Rezpegaldesleukin, a..
02/10/202308:00PRNUSNektar Therapeutics Announces Two Abstracts Accepted at EADV..
27/9/202308:00PRNUSNektar Therapeutics Announces New Clinical Study..
21/9/202319:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202319:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202319:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202319:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202319:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202319:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202316:06EDGAR2Form 144 - Report of proposed sale of securities
13/9/202308:00PRNUSNektar Therapeutics Announces Promising New Data from Phase..
08/9/202316:16EDGAR2Form 8-K - Current report
06/9/202317:00PRNUSNektar Therapeutics to Host Virtual Investor & Analyst Event..
17/8/202319:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202319:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
NKTR
Nektar Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados